Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient ...

Caribou Biosciences has linked its CAR-T cell therapy candidate to 17.1-month median progression-free survival (PFS), adding to evidence that the off-the-shelf treatment can match the efficacy of ...

Through it all, the family says they refuse to fall apart.

MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI ...

Background A 45-year-old woman with small-cell lung cancer presented to a hospital emergency department in an acute confusional state, with blurred vision and mild headache. Following progressively ...

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses ...

These post-hoc analyses demonstrate that BRIUMVI provided significant and consistent improvements across multiple clinical and MRI endpoints compared to teriflunomide in patients who had not received ...

MS is inherently unpredictable. A person may appear physically stable during one evaluation but experience significant ...

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only Safe ...

Karl Bjørnar Alstadhaug (born 1972), specialist in neurology, senior consultant and professor. The author has completed the ICMJE form and reports the following conflicts of interest: He has received ...